Cynthia Collins served as Chief Executive Officer of Editas Medicine, Inc. (Nasdaq:EDIT) from March 2019 to February 2021.. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc. and Chief Executive Officer/General Manager of General Electric’s Healthcare Cell Therapy and Lab Businesses and GE’s Clarient Diagnostics. Prior to GE, Ms. Collins served as CEO of GenVec (NASDAQ:GNVC), a vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses.
Ms. Collins serves as a member of the board of directors of Poseida Therapeutics, a cell and gene therapy company; DermTech, Inc., a molecular diagnostic company; and Nutcracker Therapeutics, Inc., a privately held company.
Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA from The University of Chicago Booth School of Business. She is currently a member of the boards of Poseida Therapeutics (PSTX) and DermTech, Inc. (DMTK).